{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T17:23:35Z","timestamp":1768152215800,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.semarthrit.2015.04.002","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T11:46:06Z","timestamp":1433591166000},"page":"S2-S8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"S","title":["Clinical trial development for biosimilars"],"prefix":"10.1016","volume":"44","author":[{"given":"Rieke","family":"Alten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce N.","family":"Cronstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.04.002_bib1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrrheum.2012.84","article-title":"The advent of biosimilar therapies in rheumatology\u2014\u201cO brave new world\u201d","volume":"8","author":"Scheinberg","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"4 Suppl. 73","key":"10.1016\/j.semarthrit.2015.04.002_bib3","first-page":"S102","article-title":"Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues","volume":"30","author":"Lapadula","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib4","unstructured":"Congress of the United States of America. Patient protection and affordable care act, \u3008http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-111publ148\/pdf\/PLAW-111publ148.pdf\u3009; 2010 [accessed 18.12.13]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib5","unstructured":"US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf\u3009; 2012 [accessed 21.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib6","unstructured":"US Food and Drug Administration. Guidance for industry. Quality considerations in demonstrating biosimilarity to a reference protein product, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291134.pdf\u3009; 2012 [accessed 21.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib7","unstructured":"US Food and Drug Administration. Guidance for industry. Formal meetings between the FDA and biosimilar biological product sponsors or applicants, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM345649.pdf\u3009; 2013 [accessed 25.02.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib8","unstructured":"US Food and Drug Administration. Guidance for industry. Biosimilars: questions and answers regarding implementation of the biological price competition and innovation act of 2009, \u3008http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm259797.htm\u3009; 2012 [accessed 25.02.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib9","unstructured":"US Food and Drug Administration. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product, \u3008http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm397017.pdf\u3009; 2014 [accessed 19.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib10","unstructured":"US Food and Drug Administration. Guidance for industry. Reference product exclusivity for biological products filed under 351(a) of the PHS Act, \u3008http:\/\/www.fdanews.com\/ext\/resources\/files\/08\/08-04-14-BiosimilarsExclusivityGuidance.pdf\u3009; 2014 [accessed 19.08.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib11","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003517.pdf\u3009; 2005 [accessed 1812.13]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib12","unstructured":"European Medicines Agency. European public assessment reports\u2014biosimilars, \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter keywords&searchType=name&alreadyLoaded=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&jsenabled=false&searchGenericType=biosimilars&orderBy=authDate&pageNo=1\u3009; 2014 [accessed 22.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib13","unstructured":"GaBI Online. FDA accepts biosimilar filgrastim application, \u3008http:\/\/www.gabionline.net\/Biosimilars\/News\/FDA-accepts-biosimilar-filgrastim-application\u3009; 2014 [accessed 19.08.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib14","unstructured":"GaBI Online. FDA receives application for monoclonal antibody biosimilar, \u3008http:\/\/www.gabionline.net\/Biosimilars\/News\/FDA-receives-application-for-monoclonal-antibody-biosimilar\u3009; 2014 [accessed 11.09.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2011.08.034","article-title":"Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know","volume":"66","author":"Strober","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdm345","article-title":"The challenge of biosimilars","volume":"19","author":"Mellstedt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4155\/bio.13.307","article-title":"Bioanalytical challenges of biosimilars","volume":"6","author":"Islam","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib18","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1185\/03007995.2012.686902","article-title":"Comparability and biosimilarity: considerations for the healthcare provider","volume":"28","author":"Lee","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiestl","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib20","unstructured":"International Conference on Harmonization. ICH Harmonized Tripartite Guideline. Comparability of biotechynological\/biological products subject to changes in their manufacturing process, \u3008http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q5E\/Step4\/Q5E_Guideline.pdf\u3009; 2004 [accessed 01.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.biologicals.2011.06.024","article-title":"Clinical programs in the development of similar biotherapeutic products: rationale and general principles","volume":"39","author":"Berghout","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib22","unstructured":"The Merck Manual: Professional Edition. Overview of pharmacokinetics, \u3008http:\/\/www.merckmanuals.com\/professional\/clinical_pharmacology\/pharmacokinetics\/overview_of_pharmacokinetics.html\u3009; 2014 [accessed 04.02.15]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00063030-200923010-00005","article-title":"Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial","volume":"23","author":"Lubenau","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-013-0036-3","article-title":"Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab","volume":"27","author":"Visser","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib25","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib28","unstructured":"European Medicines Agency. Assessment report. Inflectra, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002778\/WC500151490.pdf\u3009; 2013 [accessed 08.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib29","unstructured":"US Food and Drug Administration. Guidance for industry. Immunogenicity assessment for therapeutic protein products, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM338856.pdf\u3009; 2013 [accessed 14.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","article-title":"Clinical pharmacokinetics and use of infliximab","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib31","unstructured":"World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs), \u3008http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf\u3009; 2009 [accessed 25.02.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib32","unstructured":"Velengtas P, Mohr P, Messner DA, National Pharmaceutical Council. Making informed decisions: assessing the strengths and weaknesses of study designs and analytic methods for comparative effectiveness research, \u3008http:\/\/www.npcnow.org\/system\/files\/research\/download\/experimental_nonexperimental_study_final.pdf\u3009; 2012 [accessed 01.07.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/imj.12292","article-title":"Biosimilars: how similar?","volume":"44","author":"Strand","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10637-012-9899-2","article-title":"Clinical trial design in biosimilar drug development","volume":"31","author":"Dranitsaris","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib35","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-203198","article-title":"Biosimilars to treat inflammatory arthritis: the challenge of proving identity","volume":"72","author":"Kay","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib36","series-title":"Kelley\u2019s Textbook of Rheumatology","first-page":"32-1","article-title":"Clinical trial design and analysis","author":"Landewe","year":"2013"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib37","unstructured":"US Food and Drug Administration. Guidance for industry. Non-inferiority clinical trials, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM202140.pdf\u3009; 2010 [accessed 10.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/apt.12477","article-title":"Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases","volume":"38","author":"Rinaudo-Gaujous","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/ar2418","article-title":"The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?","volume":"10","author":"Smolen","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2015.04.002_bib42","unstructured":"US Food and Drug Administration. Guidance for industry. Adaptive design clinical trials for drugs and biologics, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm201790.pdf\u3009; 2010 [accessed 08.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib43","unstructured":"European Medicines Agency. Guideline on similar biological medical products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/06\/WC500144124.pdf\u3009; 2013 [accessed 14.01.14]."},{"key":"10.1016\/j.semarthrit.2015.04.002_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4161\/mabs.3.3.15475","article-title":"Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany","volume":"3","author":"Reichert","year":"2011","journal-title":"MAbs"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T22:22:49Z","timestamp":1537568569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0049017215000645"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.04.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial development for biosimilars","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}